Advanced Eczema Treatments: The Complete Guide to Biologics and JAK Inhibitors

For many people, eczema is kept in check with moisturizers, gentle skincare, and the occasional topical medication. But for those living with moderate-to-severe atopic dermatitis that keeps flaring despite a solid routine, the last decade has rewritten what is possible. A new generation of systemic treatments, medicines that work throughout the body rather than on a single patch of skin, can now calm stubborn disease that older options could not touch.

These advanced treatments fall into two families: injectable biologics and oral JAK inhibitors. They are the reason a 2022 wave of approvals was widely called “game-changing,” and they have given dermatologists real choices for the first time. This guide is the big-picture map. It explains how each family works in plain language, how they compare on results and safety, what monitoring each one asks of you, and how a specialist decides between them. Think of it as the overview to read before you drill into any single drug.

One note before we start. Everything here applies to moderate-to-severe disease that a doctor has judged needs systemic treatment. If your eczema is well controlled with creams, this is not a step you need. And none of it replaces a conversation with a board-certified dermatologist or allergist.

When eczema calls for systemic treatment

Most eczema never needs a pill or an injection. The foundation of care, for every type of eczema, is barrier repair with fragrance-free emollients, gentle cleansing, and topical anti-inflammatories such as corticosteroids or calcineurin inhibitors. Systemic therapy enters the picture only when that foundation, used properly, is not enough.

European and American guidelines broadly agree on who qualifies: adults and adolescents with moderate-to-severe atopic dermatitis that is not controlled by optimized topical treatment, or for whom topical treatment is not realistic because so much of the body is involved. The EuroGuiDerm systemic-therapy guideline frames it as a shared decision, reached once the disease burden on the skin, on sleep, and on quality of life is high enough to justify a treatment that acts body-wide. Phototherapy and older immunosuppressants such as ciclosporin and methotrexate are also part of this conversation, but the targeted drugs below have moved to the front of it.

The two families, in plain language

Both biologics and JAK inhibitors work by interrupting the overactive immune signaling that drives atopic dermatitis. In eczema-prone skin, immune cells pour out a set of messenger proteins called type 2 cytokines (interleukin-4, interleukin-13, interleukin-31, and others) that inflame the skin, weaken its barrier, and switch on the nerves that produce itch. The two families turn that signaling down in different places.

Biologics are large antibody proteins, given by injection under the skin. Each one is precision-guided to grab a single target and neutralize it. Because they are proteins, they cannot be swallowed (stomach acid would destroy them), so they come as a pre-filled pen or syringe used every two to four weeks.

JAK inhibitors are small molecules taken as a daily tablet. Instead of blocking one cytokine outside the cell, they work inside it. Many different itch and inflammation signals all funnel through the same internal relay station, a set of enzymes called Janus kinases (JAK). By damping that shared relay, a JAK inhibitor quiets a broader range of signals at once. That breadth is part of why these drugs tend to act fast and hit itch hard, and also why they need closer monitoring. The same JAK-STAT pathway is the target of the newer prescription creams, which I cover in this explainer on topical JAK inhibitors.

Meet the biologics

Three biologics are now approved for atopic dermatitis, all aimed at that type 2 pathway:

Dupilumab (Dupixent) is the elder statesman, first approved in 2017. It blocks the shared receptor subunit (IL-4 receptor alpha) that both interleukin-4 and interleukin-13 use, switching off the two master signals of atopic inflammation at once. It is dosed every two weeks after a loading dose and is approved down to infancy.
Tralokinumab (Adbry), approved in 2021, neutralizes interleukin-13 specifically.
Lebrikizumab (Ebglyss), approved in 2024, also targets interleukin-13, binding it in a way that allows less frequent dosing during maintenance.

The shared appeal of biologics is a clean safety record. They do not suppress the whole immune system, they need little or no routine blood monitoring, and their most notable side effect is conjunctivitis (eye inflammation), usually mild, along with reactions at the injection site.

An adult pressing a pale yellow auto-injector pen against the thigh for an at-home subcutaneous injection, the way biologics are delivered.

Meet the JAK inhibitors

Three oral JAK inhibitors round out the toolkit:

Upadacitinib (Rinvoq) and abrocitinib (Cibinqo), both approved for eczema in 2022, are selective JAK1 inhibitors.
Baricitinib (Olumiant) blocks JAK1 and JAK2. It is approved for atopic eczema in Europe and Japan, though not currently FDA-approved for eczema in the United States, where it is cleared for other conditions.

Their appeal is speed and power. As pills they are simple to take, they often calm itch within days, and at higher doses they deliver the highest levels of skin clearance of any approved systemic option. The trade-off is that they ask for more vigilance, which I come to below.

A single white tablet resting in an open palm beside a glass of water, illustrating the daily oral dosing of JAK inhibitors.

How they compare on results

This is where the large evidence reviews earn their keep, because they line every drug up against the others. A 2023 systematic review and network meta-analysis pooling 149 trials and more than 28,000 patients, prepared for the American allergy guidelines, reached a clear high-certainty conclusion. High-dose upadacitinib was among the most effective options across nearly every outcome that matters to patients, with high-dose abrocitinib close behind. Among the biologics, dupilumab, lebrikizumab, and tralokinumab landed in an intermediate-effectiveness tier, with dupilumab generally the strongest of the three. Low-dose baricitinib was among the least effective.

The one major head-to-head trial tells the same story. In the Heads Up study, a 24-week randomized comparison of oral upadacitinib against injectable dupilumab in nearly 700 adults, upadacitinib met its goal of superiority, clearing skin in more patients at the 16-week mark and easing itch faster. None of this makes dupilumab a weak drug. In people who respond, biologics tend to catch up over months of continuous use and hold their results well. It simply means that, at full dose, the oral JAK inhibitors currently sit at the top for raw, fast efficacy.

The safety trade-off

Higher peak efficacy comes with a more demanding safety profile, and this is the heart of the choice. The same reviews that crown the JAK inhibitors on efficacy also flag them as more likely to cause adverse events. JAK inhibitors carry a class boxed warning, the FDA’s strongest, covering serious infections, blood clots, major cardiovascular events, malignancy, and death.

It helps to understand where that warning comes from. Much of it is extrapolated from a large safety study of an older JAK inhibitor in rheumatoid arthritis patients who were over 50 and already carried heart-disease risk factors, a very different group from a healthy 30-year-old with eczema. Regulators have responded with caution rather than alarm. The European Medicines Agency advises extra care, and often a different choice, in people over 65, current or former smokers, and those with cardiovascular, clotting, or cancer risk. Day to day, the more common JAK side effects are milder: acne, nausea, headache, and reactivation of cold sores or shingles.

Biologics, by contrast, are consistently rated among the safest systemic options. Their main downside is conjunctivitis, and they sidestep the broader immune and metabolic effects that make JAK monitoring necessary.

Monitoring: what each path asks of you

The practical difference in monitoring is large. Starting a JAK inhibitor means baseline bloodwork plus screening for tuberculosis and hepatitis, then periodic blood tests to watch your blood counts, cholesterol, and liver enzymes. Vaccinations, including the shingles vaccine, are usually brought up to date first. Biologics ask far less: no mandatory lab schedule for dupilumab, and a simple injection routine you can do at home. For someone who dislikes blood draws, the injection wins on simplicity. For someone who hates needles, the daily pill does.

How a dermatologist chooses

Because no single drug is right for everyone, guidelines stress shared decision making. Your dermatologist weighs a handful of factors with you:

Speed and severity. If itch is unbearable or the disease is severe and you want the fastest, deepest relief, a JAK inhibitor is attractive. If a steadier, lower-maintenance path appeals more, a biologic fits.
Pill versus injection. A real personal preference, and a legitimate tiebreaker.
Age and health history. Older age, smoking, or a history of clots, heart disease, or cancer tilts the balance toward a biologic.
Pregnancy and family planning. Biologics, and dupilumab especially because it has the most accumulated data, are generally preferred when pregnancy is a consideration.
Other atopic conditions. Dupilumab also treats asthma and other type 2 diseases, which can make it a tidy single choice for someone who has more than one.
Cost and insurance. All of these drugs are expensive, and coverage, prior authorization, and manufacturer support programs often shape what is actually startable.

It is normal to try one drug and switch if it does not deliver or does not agree with you. Having several good options means a first choice is rarely a final one. Never stop or change a prescribed treatment on your own, though. Sudden changes can trigger a rebound flare, and your doctor can plan any switch safely.

Choosing between a biologic and a JAK inhibitor is a shared decision you make with your dermatologist. Photo: "A doctor and patient engaging in a positive consultation in a bright clinic setting." by cottonbro studio on Pexels.

The bottom line

A decade ago, someone with severe eczema that resisted creams had few good options. Today there are two families of targeted systemic treatments: injectable biologics that are gentle and steady, and oral JAK inhibitors that are fast and powerful but ask for closer monitoring. The large network meta-analyses put the full-dose JAK inhibitors slightly ahead on raw efficacy and the biologics ahead on safety, and the right pick depends entirely on the person taking it.

If your moderate-to-severe eczema is not responding to topical care, this is the conversation to have with a board-certified dermatologist or allergist. Bring your history, your priorities (speed, convenience, safety), and your questions. The point of this expanding toolkit is that, more than ever before, a plan can be built around you.